Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senna vs. PEG 3350 for Retentive Encopresis in Children
NCT07604025Phase 1Not yet recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sennosides in encopresis and functional constipation (FC) (2 arms), sponsored by Shaare Zedek Medical Center. Primary endpoint: Number of fecal incontinence incidents per week at 3 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sennosides
03
Conditions
encopresisfunctional constipation (FC)
Beyond the preview
Go deeper on NCT07604025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604025.